olaparib In December, 2014, the EMA and US FDA approved olaparib as monotherapy (at 400 mg taken twice per day) for patients with germline BRCA mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
rucaparib, December 19, 2016 the US FDA granted accelerated approval for previously treated BRCA-mutant ovarian cancer [REF].